Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc (TSX: TH )

2.960 -0.030 (-1.00%)
Streaming Delayed Price Updated: 10:18 AM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theratechnologies Inc

< Previous 1 2 3 Next >
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Resumed Production of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at Upcoming Investor Conferences in September
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
From Theratechnologies
Via GlobeNewswire
Theratechnologies Appoints Elina Tea to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Update on its Preclinical Oncology Research Program
From Theratechnologies
Via GlobeNewswire
Theratechnologies Appoints Jordan Zwick to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.